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Impact of renal dysfunction on 
the choice of diagnostic imaging, 
treatment strategy, and outcomes 
in patients with stable angina
takao Kato  1, Yukari Uemura2, Masanao Naya3, Mitsuru Momose4, Naoya Matsumoto5, 
eriko suzuki6, satoshi Hida7, takatomo Nakajima8, takao Yamauchi9 & Nagara tamaki6
We investigated the interaction between the prognostic impact of a decrease in eGFR and the choice 
of initial diagnostic imaging modality for coronary artery disease. Out of 2878 patients who enrolled 
in the J-COMPASS study, 2780 patients underwent single photon emission computed tomography 
(speCt), coronary computed tomography (Ct) angiography, or coronary angiography (CAG) as an initial 
diagnostic test. After excluding patients with routine hemodialysis or lacked serum creatinine levels, 
2096 patients in the non-decreased eGFR group (eGFR ≥ 60 ml/min/1.73 m2) and 557 patients in the 
decreased eGFR group (eGFR < 60 ml/min/1.73 m2) were analyzed in this study. Major adverse cardiac 
events, including death, myocardial infarction, heart failure hospitalization, and late revascularization, 
were followed, with a median follow-up duration of 472 days. SPECT or CAG was preferable to CT in 
patients in the decreased eGFR group (p < 0.0001 and p = 0.0024, respectively). There was a marginally 
significant interaction between the prognostic impact of a decrease in eGFR and the choice of diagnostic 
imaging modality (interaction-p = 0.056). A decrease in eGFR was not associated with a poor outcome 
in patients who underwent Ct, while a decrease in eGFR was associated with poor outcomes in patients 
who underwent speCt or CAG. In conclusion, the prognostic impact of a decrease in eGFR tended to be 
different among the initial imaging modalities.
Chronic kidney disease (CKD) caused more deaths worldwide in 2015 than in 20051. Patients with CKD most 
commonly die from cardiovascular diseases2,3. Furthermore, the presence of CKD has a negative impact on the 
short- and long-term prognoses of cardiovascular diseases2. Positive findings of ischemia are more prevalent with 
a decline in creatinine clearance4.
It is important to choose the appropriate diagnostic imaging modality to detect coronary artery disease 
(CAD) in symptomatic patients with suspected CAD. Although the superiority of anatomical testing when com-
pared with functional testing has long been debated, Douglas et al. reported that a strategy of anatomical testing 
with CTA, did not reduce the incidence of MACE as compared with functional testing5. However, there were 
no data available on renal function in the PROMISE trial5. In patients with renal dysfunction, the use of the 
contrast-enhanced medium should be minimal. In addition, comorbidities accelerate atherosclerosis, leading to 
calcification of the coronary artery. Thus, the choice of imaging modality in patients with renal dysfunction may 
be different from that in patients with normal renal function. Coronary computed tomography (CT) angiogra-
phy, myocardial perfusion imaging (MPI), and coronary angiography (CAG) are three major imaging modali-
ties used to diagnose CAD in patients with angina. There are many studies revealing the utility of each of these 
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diagnostic imaging modalities in patients with renal dysfunction6–14. However, there have been no comparisons 
among these modalities, nor any data on the choice of modality in patients with renal dysfunction. The Japanese 
Coronary-Angiography or Myocardial Imaging for Angina Pectoris Study (J-COMPASS) Multicenter Study15, a 
study with a non-random and physician-referred design, reported that the choice of initial imaging modality was 
linked to the subsequent revascularization therapy and risk of major adverse cardiac events (MACE) at one year 
in symptomatic patients with CAD. In the original study, the use of single photon emission computed tomogra-
phy (SPECT) and CT was associated with a lower risk of MACE than was the use of invasive CAG; however, the 
use of CT and CAG was associated with more frequent elective revascularization15.
In this sub-study, we sought to test whether all three initial diagnostic tests for CAD (CT, SPECT, and CAG) are 
associated with MACE for patients with a decrease in eGFR. We also aimed to see if there is any difference in the 
treatment strategy by a different type of initial diagnostic test between patients with and without a decrease in eGFR.
Methods
patients. The design and main trial results of the J-COMPASS study have been published previously15. A total 
of 2,878 consecutive patients with suspected stable angina, from 81 centers in Japan with high-end diagnostic 
facilities, were enrolled. On the basis of the results of the initial tests and other clinical findings, well-trained car-
diologists determined the initial diagnostic imaging modality to be used and the treatment strategy. Among these 
patients, 2780 patients who underwent SPECT, CT, or CAG as an initial diagnostic test and who had been rou-
tinely followed up were analyzed in the J-COMPASS study15. Symptomatic patients advised to undergo SPECT, 
CT, or CAG as the initial diagnostic test for suspected chronic CAD were enrolled. All patients underwent either 
stress SPECT (n = 1205), CT (n = 625), or CAG (n = 950) as an initial test for the diagnosis of CAD. The exclu-
sion criteria of the original study were acute coronary syndrome at presentation or within a short period after the 
initial test, and a history of myocardial infarction (MI) or revascularization therapy.
In this sub-study, we excluded patients who had undergone routine hemodialysis (n = 58) or lacked data on the 
serum creatinine levels (n = 69). Thus, the final study population included 2653 patients (Fig. 1 and Supplementary 
Table 1). We calculated the estimated glomerular filtration rate (eGFR) as follows: eGFR (ml/min/1.73 m2) = 194 × 
Cr−1.094 × (Age)−0.287 in men and 194 × Cr−1.094 × (Age)−0.287 × 0.739 in women16, and classified patients according 
to their eGFR. We analyzed patients with stage 2 CKD or lower (eGFR ≥ 60 ml/min/1.73 m2; non-decreased eGFR 
group) and stage 3 CKD or higher (eGFR < 60 ml/min/1.73 m2; decreased eGFR group). Comorbidities were based 
on the physician’s evaluation. Cerebrovascular disease was defined by stroke or vascular disease requiring the inter-
vention by a neurosurgeon. Malignancy was defined according to various cancers and hematologic neoplasm.
treatment strategy and outcome measures. On the basis of the results of the initial tests and other 
clinical findings, the physicians chose the treatment strategy15. The treatment strategies included (1) medical 
therapy, which indicated medical therapy with same medication at the same dose after the initial test; (2) escala-
tion of medical therapy, which indicated an increase in the dose of the same medication or introduction of new 
medication, and (3) intervention and escalation of medical therapy. The end-point was MACE: death, acute MI, 
heart failure hospitalization and late revascularization (>3 months) in accordance with the original study15.
Definition of obstructive CAD in coronary CTA and CAG and functionally significant result in 
speCt. We adopted the definitions used by the J-COMPASS study15. On CTA or CAG, patients with 1 or more 
diseased vessel (>50% diameter stenosis in segment 5, 6, 7, 11, 13, 1, 2, or 3) were considered to have a significant 
stenosis17,18. For the SPECT group, SPECT images were divided into 17 segments, each of which was scored five 
Figure 1. Patient flowchart. SPECT = single photon emission computed tomography, CT = computed 
tomographic angiography, CAG = coronary angiography, CAD = coronary artery disease, 
J-COMPASS = Japanese Coronary-Angiography or Myocardial Imaging for Angina Pectoris Study, 
eGFR = estimated glomerular filtration rate.
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points under both stress and rest conditions (0, normal; 1, mildly reduced; 2, moderately reduced; 3, severely 
reduced; 4, absent) according to the American Heart Association criteria19 and summed stress score (SSS) ≥ 2 





p value(n = 2096) (n = 557)
Age (years) 65.47 10.43 70.87 8.94 <0.0001
Age ≥60 years old* 1476 70.4% 493 88.5% <0.0001
Female* 888 42.4% 211 37.9% 0.056
Height (cm) 159.32 8.99 158.8 8.99 0.23
Weight (Kg) 60.98 11.71 61.51 10.64 0.33
BMI (kg/m2)*,|| 23.92 3.49 24.33 3.32 0.014
Systolic BP (mmHg) 137.09 19.29 137.96 19.49 0.35
Diastolic BP (mmHg) 78.2 11.97 75.8 11.72 <0.0001
Smoking* 520 24.8% 128 23.0% 0.37
Hypertension* 1149 54.8% 386 69.3% <0.0001
Dyslipidemia* 1006 48.0% 259 46.5% 0.53
Diabetes* 584 27.9% 181 32.5% 0.032
Hyperuricemia* 99 4.7% 50 9.0% 0.0001
Familial history of CAD 277 13.2% 68 12.2% 0.53
Cerebrovascular disease 140 6.7% 65 11.7% <0.0001
PAD 42 2.0% 35 6.3% <0.0001
Atrial fibrillation 57 2.7% 35 6.3% <0.0001
COPD* 24 1.1% 7 1.3% 0.83
Disease of aorta* 20 1.0% 16 2.9% 0.001
Malignancy 51 2.4% 17 3.1% 0.41
eGFR (mL/min/1.73 m2) 82.36 16.76 49.35 10.37 <0.0001
CCS*
Class 1 1345 64.2% 365 65.5% 0.064
Class 2 636 30.3% 174 31.2%
Class 3 69 3.3% 15 2.7%
Class 4 46 2.2% 3 0.5%
NYHA*
I 1765 84.2% 471 84.6% 0.12
II 279 13.3% 78 14.0%
III 23 1.1% 7 1.3%
IV 29 1.4% 1 0.2%
Initial diagnostic modalities
SPECT: n, % for those who underwent SPECT 846/1115 75.9% 269/1115 24.1% <0.0001
Subsequent test
Functional abnormality 381/846 45.1% 127/269 47.2% 0.532
CT 21/846 2.5% 3/269 1.1% 0.23
CAG 147/846 17.4% 122/269 45.4% <0.0001
CT: n, % for those who underwent CT 531/618 85.9% 87/618 14.1% <0.0001
Subsequent test
Obstructive CAD 201/531 38.2% 49/87 57.0% 0.001
SPECT 47/531 8.9% 7/87 8.1% 1.00
CAG 190/531 35.8% 42/87 48.3% 0.031
CAG: n, % for those who underwent CAG 719/920 78.2% 201/920 21.8% <0.0001
Subsequent test
Obstructive CAD 352/719 49.0% 122/201 60.7% 0.0032
CT 12/719 1.7% 2/201 1.0% 0.75
SPECT 29/719 4.0% 15/201 7.5% 0.060
Table 1. Patient characteristics. Values are number (% of column total, except where indicated) or mean (SD). 
Proportion of patients in each diagnostic test represents % of patients who underwent each diagnostic test 
included in the study, with or without decreased eGFR. P values were calculated from a chi-square test for 
categorical variables, Continuous variables were expressed as means (standard deviation [SD]). Continuous 
variables were compared using the Student’s t-test between 2 groups. ||Body mass index was calculated as 
weight in kilograms divided by height in meters squared. *Potential risk-adjusting variables selected for Cox 
proportional hazard models. CCS was adjusted for Class 2 or more, and NYHA functional class was adjusted 
for II or more. BP = blood pressure, BMI = body mass index, CAD = coronary artery disease, PAD = peripheral 
artery disease, COPD = chronic obstructive pulmonary disease, eGFR = estimated glomerular rate, 
CCS = Canadian Circulation Society, NYHA = New York Heart Association, SPECT = single photon emission 
computed tomography, CT = computed tomography angiography, CAG = coronary angiography.
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ethics. All methods were carried out according to the principles of the Declaration of Helsinki. The study 
protocol was approved by the institutional review board of each participating center (Appendix). All participating 
patients provided written/oral informed consent before study enrollment15. We anonymized the patient record/
information before analysis.
statistical analysis. In the present analysis, (1) we compared the baseline characteristics of patients belong-
ing to the non-decreased eGFR and decreased eGFR groups, (2) we investigated whether a decrease in eGFR 
affects the selection of the initial diagnostic modality and treatment, and (3) we compared the outcome measures 
between the two patient groups and tested the interaction of its impact on prognosis and modalities.
Categorical variables were expressed as numbers and percentages and were compared using a chi-square 
test. Continuous variables were expressed as means (standard deviation [SD]) or median and interquartile range 
[IQR]. Continuous variables were compared using Student’s t-test between 2 groups and one-way analysis of 
variance among 3 groups.
To analyze the factors associated with the initial diagnostic modalities, we used a multinomial logistic regres-
sion model involving the following 13 potential independent, clinically relevant variables: age ≥60 years; sex; 
body mass index; presence of hypertension, dyslipidemia, diabetes, hyperuricemia, chronic obstructive pul-
monary disease, and aortic disease (aneurysm or dissection); Canadian Circulation Society class 2 or higher21; 
current smoking; New York Heart Association (NYHA) functional class 2 or higher22; and a decrease in eGFR 
(Table 1). The adjusted odds ratios (ORs) relative to the choice of CT and 95% confidence intervals (CIs) were 
calculated. We set the choice of CT as a reference because the proportion of decrease in the eGFR was small. 
Next, to analyze the factors associated with the treatment strategies, we also used a multinomial logistic regres-
sion model including 15 variables: that is, the above-mentioned 13 variables and diagnostic modalities. When 
assessing the diagnostic modalities, we set SPECT as a reference according to the original J-COMPASS study15. 
Third, the Kaplan–Meier method was used to estimate the MACE rate between the decreased or non-decreased 
eGFR groups; the log-rank test was used for univariate comparisons. To compare the risks between the decreased 
SPECT CT CAG P
Age 70.95 9.19 70.34 8.74 70.99 8.73 0.832
Age ≥60 years old 236 87.7% 76 87.4% 181 90.0% 0.690
Female 110 40.9% 36 41.4% 65 32.3% 0.128
Height (cm) 158.89 9.01 158.55 9.05 158.8 8.97 0.955
Weight (Kg) 61.42 10.97 61.36 11.18 61.7 9.99 0.953
BMI (kg/m2) 24.25 3.27 24.31 3.47 24.44 3.32 0.824
Systolic Bp (mmHg) 137.42 19.36 138.95 20.84 138.25 19.15 0.787
Diastolic Bp (mmHg) 75.3 11.11 76.8 11.48 76.02 12.62 0.552
Smoking 54 20.1% 16 18.4% 58 28.9% 0.044
Hypertension 185 68.8% 62 71.3% 139 69.2% 0.907
Dyslipidemia 114 42.4% 47 54.0% 98 48.8% 0.121
Diabetes 77 28.6% 26 29.9% 78 38.8% 0.056
Hyperuricemia 21 7.8% 9 10.3% 20 10.0% 0.643
Familial history of CAD 24 8.9% 14 16.1% 30 14.9% 0.070
Cerebrovascular disease 33 12.3% 10 11.5% 22 10.9% 0.906
PAD 14 5.2% 1 1.1% 20 10.0% 0.011
Atrial fibrillation 22 8.2% 4 4.6% 9 4.5% 0.205
COPD 3 1.1% 1 1.1% 3 1.5% 0.932
Disease of aorta 13 4.8% 2 2.3% 1 0.5% 0.020
Malignancy 8 3.0% 0 0.0% 9 4.5% 0.127
eGFR (mL/min/1.73 m2) 48.61 9.92 51.58 8.35 49.39 11.58 0.068
CCS
Class 1 214 79.6% 54 62.1% 97 48.3% <0.0001
Class 2 51 19.0% 32 36.8% 91 45.3%
Class 3 4 1.5% 0 0.0% 11 5.5%
Class 4 0 0.0% 1 1.1% 2 1.0%
NYHA
I 240 89.2% 77 88.5% 154 76.6% 0.004
II 27 10.0% 10 11.5% 41 20.4%
III 2 0.7% 0 0.0% 5 2.5%
IV 0 0.0% 0 0.0% 1 0.5%
Table 2. Patients characteristics among SPECT, CT and CAG groups in decreased eGFR group. Continuous 
variables were expressed as means (standard deviation [SD]). Categorical variables were expressed as numbers 
and %. BMI = body mass index, BP = blood pressure, CAD = coronary artery disease, PAD = peripheral 
artery disease, eGFR = estimated glomerular rate, CCS = Canadian Circulation Society, NYHA = New York 
Heart Association, SPECT = single photon emission computed tomography, CT = computed tomography, 
CAG = coronary angiography.
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Variables Reference OR 95%CI p value
Factors associated with the use of SPECT
eGFR < 60 ml/min/1.73 m2 ≥60 1.96 1.49 2.59 <0.0001
Age ≥60 y.o. <60 0.85 0.67 1.08 0.18
Female male 0.94 0.76 1.17 0.57
BMI (kg/m2) 1 increase 0.99 0.96 1.03 0.70
Smoking no 0.84 0.65 1.10 0.20
Hypertension no 0.87 0.70 1.08 0.20
Dyslipidemia no 0.91 0.74 1.12 0.35
Diabetes no 1.10 0.87 1.38 0.45
Hyperuricemia no 0.85 0.54 1.36 0.50
COPD no 2.38 1.04 6.46 0.058
Disease of aorta no 1.08 0.62 1.97 0.79
CCS Class 2 or more Class 1 0.58 0.45 0.73 <0.0001
NYHA II or more I 0.52 0.37 0.72 <0.0001
Factors associated with the use of CAG
eGFR < 60 ml/min/1.73 m2 ≥60 1.56 1.17 2.08 0.0024
Age ≥60 y.o. <60 1.16 0.90 1.49 0.26
Female male 0.65 0.52 0.81 0.0002
BMI (kg/m2) 1 increase 1.02 0.99 1.05 0.26
Smoking no 1.41 1.09 1.82 0.009
Hypertension no 0.96 0.77 1.20 0.74
Dyslipidemia no 0.96 0.77 1.18 0.67
Diabetes no 1.15 0.91 1.46 0.24
Hyperuricemia no 0.85 0.54 1.34 0.47
COPD no 3.96 1.78 10.54 0.0021
Disease of aorta no 0.87 0.48 1.65 0.67
CCS Class 2 or more Class 1 1.57 1.24 1.99 0.0002
NYHA II or more I 0.94 0.70 1.25 0.66
Factors associated with the escalation of medical therapy relative to the medical therapy
CT SPECT 1.42 1.12 1.81 0.0045
CAG SPECT 2.15 1.68 2.76 <0.0001
Age ≥60 <60 1.13 0.90 1.41 0.30
Female male 0.77 0.63 0.95 0.016
BMI (kg/m2) 1 increase 1.03 1.00 1.06 0.027
Smoking no 0.88 0.68 1.13 0.31
Hypertension no 2.12 1.74 2.60 <0.0001
Dyslipidemia no 1.13 0.93 1.39 0.23
Diabetes no 1.89 1.47 2.43 <0.0001
Hyperuricemia no 0.97 0.61 1.58 0.91
COPD no 1.24 0.60 2.76 0.57
Disease of aorta no 2.91 1.59 5.72 0.0010
eGFR < 60 ml/min/1.73 m2 ≥60 1.43 1.10 1.86 0.0075
CCS Class 2 or more Class 1 1.38 1.08 1.77 0.012
NYHA II or more I 1.14 0.82 1.61 0.44
Factors associated with the intervention therapy relative to the medical therapy
CT SPECT 1.63 1.20 2.22 0.0017
CAG SPECT 5.30 4.00 7.05 <0.0001
Age ≥60 <60 1.67 1.26 2.22 0.0003
Female male 0.34 0.26 0.44 <0.0001
BMI (kg/m2) 1 increase 1.03 0.99 1.07 0.10
Smoking no 1.03 0.78 1.37 0.83
Hypertension no 2.16 1.69 2.76 <0.0001
Dyslipidemia no 2.02 1.59 2.57 <0.0001
Diabetes no 3.89 2.96 5.13 <0.0001
Hyperuricemia no 0.82 0.49 1.39 0.45
Continued
6Scientific RepoRts |          (2019) 9:7882  | https://doi.org/10.1038/s41598-019-44371-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
or non-decreased eGFR groups, a multivariable Cox proportional hazard model was developed for MACE. The 
results are expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). We selected 13 clinically relevant 
risk-adjusting variables, as mentioned above. Subgroup analyses for MACE were also performed with each diag-
nostic modality. Finally, we tested the interaction between the prognostic impact of renal dysfunction and each 
diagnostic modality. As a Supplementary Analysis, we have analyzed the MACE rates in the CT, SPECT, and CAG 
groups among patients with renal dysfunction using the Kaplan–Meier method.
Statistical analysis of the data was performed by the study biostatistician (YU) using SAS 9.4 software (SAS 
Institute Inc., Cary, North Carolina). All reported P values were 2-tailed, and P values < 0.05 were considered 
statistically significant.
Results
patient characteristics. The characteristics of patients in the non-decreased eGFR (N = 2096) and 
decreased eGFR (N = 557) groups are shown in Table 1. Patients in the decreased eGFR group were older (mean: 
70.8 vs. 65.4 years, p < 0.0001) and had a higher prevalence of hypertension (69.3 vs. 54.8%, p < 0.0001), diabetes 
(32.5 vs. 27.9%, p = 0.032), hyperuricemia (9.0 vs. 4.7%, p = 0.0001), and peripheral (6.3 vs. 2.0%, p < 0.0001) and 
cerebral vascular diseases (11.7 vs. 6.7%, p < 0.0001).
Impact of renal dysfunction on diagnostic imaging modalities. The frequency of SPECT between 
the non-decreased eGFR and decreased eGFR groups was 75.9% and 24.1%, respectively (p < 0.0001), while that 
of CT was 85.9% and 14.1% (p < 0.0001) and that of CAG was 78.2% and 21.8% (p < 0.0001; Table 1). The patient 
characteristics with each modality in the decreased eGFR group are presented in Table 2 and are consistent with 
those in the original J-COMPASS study15. In brief, patients who underwent CAG were more likely to be habitual 
smokers, have peripheral artery or aortic disease, and have high-grade symptoms of angina and dyspnea (Table 2 
and Supplementary Table 2). After adjusting for confounders, the odds ratio for a higher likelihood to undergo 
SPECT rather than CT was 1.96 for patients in the decreased eGFR group relative to patients in the non-decreased 
eGFR group (p < 0.0001), and the odds ratio for a higher likelihood to undergo CAG rather than CT was 1.56 for 
patients in the decreased eGFR group relative to those in the non-decreased eGFR group (p = 0.0024) (Table 3). 
Renal dysfunction was significantly associated with the choice of initial diagnostic imaging modality.
Impact of renal dysfunction on the treatment strategies. There were differences in treatment strat-
egies between the decreased eGFR and non-decreased eGFR groups in the entire cohort (Fig. 2A) or in patients 
underwent SPECT or CAG (Fig. 2B–D). After adjusting for confounders, including the initial imaging modality 
(Table 3), the decrease in eGFR was significantly associated with an escalation of medical therapy (OR 1.43, 95% 
CI 1.10–1.86, p = 0.0075) and intervention plus an escalation of medical therapy (OR 1.63, 95% CI 1.21–2.21, 
p = 0.0015).
Association with CKD stage and the impact of diagnostic imaging modalities on the outcome 
measures. The median follow-up duration after enrollment was 472 (IQR: 180.93) days, with a 96.2% 
follow-up rate at 1 year. A crude Kaplan-Meier curve for MACE showed a significantly lower MACE rate among 
patients in the non-decreased eGFR group (Fig. 3A). After adjusting for confounders, the risk of MACE in the 
decreased eGFR group was significantly higher relative to that in the non-decreased eGFR group (Table 4). When 
stratified by modality, the crude Kaplan-Meier curves showed different impacts of a decrease in eGFR on MACE 
among the modalities; the risk of MACE in the decreased eGFR group relative to that in the non-decreased 
eGFR group was significant only on SPECT (Fig. 3B–D). After adjusting for confounders, there was a margin-
ally significant interaction between the decrease in eGFR and the prognostic impact of the diagnostic modality. 
(Table 4). Among patients in the decreased eGFR group, crude Kaplan–Meier curve analysis showed differences 
in MACEs among the three treatment groups (Fig. 3E). The prevalence of each MACE occurrence in each group 
is in Supplementary Tables 3 and 4.
Discussion
The main findings of this study were as follows: 1) in patients in the decreased eGFR group, SPECT or CAG 
was preferred to CT as an initial diagnostic modality by the attending physician; 2) Among the patients who 
underwent CT or SPECT as an initial test, the prevalence of patients who escalated medication was higher in 
patients with decreased eGFR compared to patients with non-decreased eGFR. A decrease in eGFR had an inde-
pendent association with intervention therapy for CAD; 3) On Kaplan-Meier analysis, a decrease in eGFR was 
not associated with a poor outcome in patients who underwent CT as an initial test, while a decrease in eGFR 
was associated with poor outcomes in patients who underwent SPECT or CAG as an initial test. After adjusting 
Variables Reference OR 95%CI p value
COPD no 1.84 0.87 4.23 0.13
Disease of aorta no 1.08 0.48 2.48 0.85
eGFR < 60 ml/min/1.73 m2 ≥60 1.63 1.21 2.21 0.0015
CCS Class 2 or more Class 1 3.48 2.64 4.59 <0.0001
NYHA II or more I 1.21 0.85 1.74 0.30
Table 3. Factors associated with initial diagnostic modalities and treatment strategies. OR = odds ratio, 
CI = confidence interval. Abbreviations are same as in Table 2.
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confounders, a decrease in eGFR was not associated with MACE in patients who underwent CT, while there was 
a significant association between a decrease in eGFR and MACE in patients who underwent SPECT or CAG as 
an initial test; and 4) The prognostic impact of a decrease in eGFR tended to be different among the imaging 
modalities.
Initial diagnostic imaging and renal dysfunction. SPECT was performed more often than CT in 
patients with late-stage CKD, probably because of the nephrotoxicity of the intravenous contrast. In addition, 
the high incidence of abnormal vascular calcification limits the diagnostic value of CT in patients with late-stage 
CKD23. However, CT was performed in some patients with a decrease in eGFR. This might be attributed to the 
lower cost of CT than SPECT or the fewer numbers of nuclear cardiology facilities in Japan15. The decision to 
perform CAG is often difficult in patients with CKD; however, CAG would be the first choice, without SPECT or 
CT, in the case of a high pre-test probability. We should balance the risks and potential benefits in patients with 
CKD24. In fact, patients with angina CCS of class 2 or higher were more likely to undergo CAG in the present 
study. Although the pre-test probability was not determined in the present study, we included the related factors 
in the multivariate models25.
subsequent treatment and renal dysfunction. One of the novel findings of the present study is that a 
decrease in eGFR had an impact on the subsequent treatment strategies. The original J-COMPASS study showed 
a preference for intervention therapy in patients who underwent CT and CAG compared with those who under-
went SPECT, consistently with the findings of the present study15. Moreover, renal dysfunction was independently 
associated with the treatment strategies. One reason for this may be the atherosclerotic burden in patients with 
renal dysfunction. Another reason may be comorbidities underlying the renal dysfunction, although we per-
formed extensive adjustment for confounding factors.
Interaction between the impact of renal dysfunction on outcomes and the imaging modalities. 
The decrease in eGFR was significantly associated with MACE and was an independent predictor of poor out-
comes, as previously reported3. The novel finding of this study is that we showed the Kaplan-Meier curves in the 
decreased eGFR and non-decreased eGFR groups according to the diagnostic modality. In the decreased eGFR 
group, the number of patients using CT as an initial diagnostic modality and the number of MACEs in those 
patients were very small. This indicated that patients with renal dysfunction were appropriately not considered 
for CT as an initial diagnostic imaging modality. This was generally consistent with the findings of our origi-
nal J-COMPASS study15, in which the choice of initial imaging modality was linked to the cardiovascular risk. 
CT and SPECT were suitable for patients with an intermediate pretest probability of the disease23. In our study, 
patients with renal dysfunction were preferably assessed with SPECT and CAG, which explains the differences in 
the impact of renal dysfunction on the outcomes among modalities. The recent advance in imaging protocol to 
reduce radiation exposure and decrease iodine dose or isotope tracer dose in coronary CT angiography or SPECT 
may affect the choice of diagnostic modalities. Especially, ultra-low-dose contrast coronary CT protocol26 which 
can be performed with optimal image quality minimizing the risk for radiation exposure and contrast-induced 
nephrotoxicity might be feasible for CKD patients. Because the present study is not a randomized controlled 
study, we could not evaluate the validity of the criteria for selecting diagnostic tests or the appropriateness of the 
treatment planning. In patients in the decreased eGFR group, the outcomes were getting worse in the following 
order: CT, SPECT, and CAG (Fig. 3E) without adjustment for confounders. However, because of the marginal 
significance of interaction and the small number in the CT group with renal dysfunction, we could not definitely 
conclude that the negative prognostic impact of renal dysfunction could be reduced by appropriately choosing 
the initial imaging modality. Instead, we could speculate that the optimal diagnostic test and treatment for each 
patient were determined on the basis of the clinical characteristics and renal function of each patient. This is sup-
ported by the substantial number of patients of the decreased eGFR group undergoing CAG and CT.
Figure 2. (A) The proportion of treatments in non-decreased eGFR and decreased eGFR groups in the entire 
cohort. (B) The proportion of treatments in non-decreased eGFR and decreased eGFR groups in patients 
underwent SPECT. (C) The proportion of treatments in non-decreased eGFR and decreased eGFR groups in 
patients underwent CT. (D) The proportion of treatments in non-decreased eGFR and decreased eGFR groups 
in patients underwent CAG.
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Link between diagnostic modalities and outcomes in patients with renal dysfunction. Obviously, 
it is not the diagnostic test itself but the subsequent treatment based on the findings of the diagnostic test that 
improves clinical outcomes in patients with suspected CAD. Douglas et al. reported that patients in the CT group 
underwent revascularization more frequently than did those in the initial functional test group5; however, the 
CT group did not reduce incidence of outcome compared to functional test group. In line with the evidence from 
this large randomized trial, patients with CT and CAG were more likely to undergo revascularization than were 
those with SPECT in the original J-COMPASS study15. In the present study, we showed that renal dysfunction 
was an independent factor associated with optimal medical treatment and revascularization, regardless of the 
diagnostic modality. The study was not designed to assess coronary revascularization or medical treatment and 
its appropriateness and effect on outcomes. In fact, we did not include treatment, which was dependent on the 
initial and, sometimes, subsequent diagnostic tests, in the adjustment for the outcome measures. The impact of the 
treatment after initial functional imaging on the outcomes is under investigation in an ongoing ISCHEMIA trial 
Figure 3. (A) Crude Kaplan-Meier curve for MACE. Patients in decreased eGFR group had a poor prognosis 
compared with patients in non-decreased eGFR group. (B) A crude Kaplan-Meier curve for MACE for patients 
assessed with SPECT. (C) Crude Kaplan-Meier curve for MACE for patients assessed with CT. (D) Crude 
Kaplan-Meier curve for MACE for patients assessed with CAG. When stratified by each modality, the crude 
Kaplan–Meier curves showed the different impacts of renal dysfunction on mortality among the modalities.  
(E) Crude Kaplan-Meier curve for MACE by initial diagnostic modalities in decreased eGFR group.
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(International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, NCT01471522), 
wherein invasive therapy vs. medical therapy is randomized in patients with functional ischemia; however, CT was 
not performed in the decreased eGFR group. Despite the interaction observed on initial diagnostic imaging, our 
study showed worse outcomes in the decreased eGFR group.
One of the imaging modalities for CAD not included in the preset study is positron emission tomography (PET). 
Quantitative approaches that measure MBF with PET identify multi-vessel CAD27. In addition, it is well known that 
patients with CKD with microvascular dysfunction which can be measured by PET have poor outcome while SPECT 
often underestimates microvascular dysfunction27, although it remains to be underutilized in clinical practice.
study limitations. There are some limitations in the present study. We did not analyze or collect information 
about why and how patient treatment decisions were made, including the findings of the diagnostic tests, cost28, 
coronary flow reserve in CAG, and the administered drugs. We did not verify the quality of the diagnostic imaging 
modalities at each participating center, although all centers had high-end diagnostic facilities. In addition, we did 
not collect the data on what constituted medical therapy or the escalation of medical therapy, nor on the parameters 
for the escalation of the medical therapy. In the analyses, we did not perform the analysis on whether the subsequent 
diagnostic test affects the MACE rates and subsequent treatment strategy, along with the findings of the initial diag-
nostic test. Further, we did not collect data on the indication for and type of medication used during escalation of 
medical therapy. Thus, further studies are needed to evaluate the relationship between the findings of diagnostic tests 
and subsequent tests and treatments. It is possible that there remain unmeasured confounders that affect the choice 
of modalities, treatments, and outcomes, although we conducted extensive statistical adjustment for the measured 
confounders. Tracking of the outcomes with and without revascularization would be helpful in conjunction with 
the medical treatment. The use of CT is increasing annually, and it is frequently being used for screening for CAD in 
Japan29,30. Therefore, we should be careful while generalizing the results of the present study. Finally, the impact of 
renal dysfunction on long-term prognosis is still unclear in our study population and needs to be elucidated.
Conclusions
Renal dysfunction was found to be associated with the choice of imaging modality for CAD, as well as with the 
treatment strategy for CAD. The prognostic impact of renal dysfunction tended to be different among the imaging 
modalities.
Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author 
upon reasonable request.
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